Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The game here must surely be to ramp the sp up, do a big placing, and use the proceeds to fund a proper EU clinical trial. I don't know whether the Russian data can be used to bypass a P1/2 trial, but even if just a P3 trial, it will cost multiples of their cash/liquid asset balance. Still, nothing ventured....
OK, E_B. I see the value case. So what's the catch?
Are the Poly shares freely transferable? Or in a lock up?
How much value can be placed on a Russian P3 trial? How much will it cost to replicate the whole process in the EU/UK?
Not saying this is fishy, but it is Russia, after all.
Been buying quite a few over the last month and yesterday seems to be first decent volume day, trades suggest either news next week or tipped in tomorrow's papers. I don't think they done up the website unless they expect plenty new visitors shortly.
"The Russian venture company announced the completion of the sale of the share of the fund created with its capital in Ivix to the Irish biopharmaceutical company Ovoca Bio PLC. The deal amounted to 5 million rubles, according to a statement issued on Wednesday by RVC.
The Ivix company, established in 2012, is developing innovative drugs based on the signal peptide (BP101) used to combat female infertility. The preparations were based on innovative ideas of scientists of the Institute of Molecular Genetics, Russian Academy of Sciences.
The Bioprocess Capital Ventures Fund, created with the participation of RVC capital, sold its stake in the project of the Irish biopharmaceutical company Ovoca Bio PLC for $ 5 million. Earlier, Ovoca Bio PLC acted as an investor in the second round of project investment, ”the report said.
The Bioprocess Capital Ventures Fund became an investor in the company in 2013. Six years later, the development team successfully completed the third phase of clinical trials of the drug; in September 2019, the company applied to the Ministry of Health of the Russian Federation for permission to bring the drug to the market. If the regulator approves the Ivix drug to maintain female reproductive health, it may go on sale by the end of 2020, the report said.
“During being in the portfolio of the fund, the Ivix team successfully completed all stages of the clinical trials and prepared the medicine for entering the market. An innovative drug for the violation of female reproductive dysfunctions will be in demand not only in Russia - the company already has a number of international patents and plans to implement clinical trials in the EU and the USA. Partnership with the Irish company Ovoca Bio PLC will accelerate the international expansion of the product, ”the words of the deputy general director and investment director of RVC Alexei Basov are quoted in the message."
https://www.finanz.ru/novosti/aktsii/fond-bioprocess-kepital-venchurs-vyshel-iz-chisla-investorov-kompanii-ayviks-rvk-1029195893
worth researching thoroughly before parting with the hard earned. But from my research I feel this is a compelling investment :)
I am being incredibly conservative given the this:
https://ovocabio.com/app/uploads/2020/03/Ovoca-Bio-plc-Libicore-Presentation-2019.pdf
Slide 21 outlines the two competitors market deals post FDA
Thanks I'm taking a grands worth tomorrow
no worries, for a company with a P3 approved drug that is approved for sales in a very underserved market worth $300m (Russia alone) ... £50m Cap would surely be fair given £14.5m is in cash/etc to help push their product to market.
Then with EU/US markets you can bolt on a significant amount more to the valuation ($2.25b market).
To me here the risk v reward is second to none
Cheers for the info, what are your targets in sp longterm
wouldn't expect any spikes here tomorrow personally... its very quiet at the moment! I expect a big rerating between now and June/July though as market takes positions in anticipation for Russian sales approval.
OVB own 737k POLY shares, which is a very respected gold producer. Ironically this is a Pharma company with leverage to gold through its stake in POLY.
I hate spikes, I like nice steady rerating builds. Fair value here bare bones at the moment is 25p.
£14.5m in Cash and POLY shares plus the company have paid £11m in acquiring IXIV = £26m vs £9m cap at present.
Of course one would argue the company see *significantly* more value in their IVIX than the £11m paid for it otherwise they wouldn't have recently acquired the remaining 40% stake.
I'm not deramping I've bought and sold here before on last spike. I have this share on watch. I am tempted to buy tomorrow providing it doesn't spike first thing. Made mistake of selling farn with lack of patience put ten grand in around 0.70 sold at a loss. What sort of mcap do you think this can get to plus what sort of time scales. I'm buying gold stocks at present but interested buying first thing but always look for stocks to top slice at double short term
you have 50% rise from here just to get to Cash & POLY shares value alone, let alone the huge upside of BP101 which is 100% owned and passed P3 trials in Russia.
POLY shares have gone up 50% which is hasn't been reflected at all in the share price either.
"Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia."
Russian approval for marketing and sales in Russia is due early H2 which is a $300m market and so is application for EU/US trials.
Multi ID;s dont do you any favours fella ;)
Will probably spike but Russian stocks listed in uk I've bought all went private and reading website there will be a long wait for progress plus there is a long wait from the company for news on each rns which never sustains a large rise in sp
Very Smart!
https://ovocabio.com/about-us/
Whats more interesting is they confirm 16.5m euros (£14.5m) held in cash and liquid assets (POLY shares)! Wow. This is way higher than my predictions.
£9m Cap
no debt
Then huge upside of 100% owned BP-101 priced at a negative EV!
Opportunity!
Just bought 50k shows as a sell typical.
Seems to be a bit of activity after days/weeks of nothing
Average trading volumes way up.
News must be on the way soon.
Yep on a technical analysis point of view holding over 12p signals a big break out so this is looking good for a big move. Itll get chased as soon as its up 50% same as always
OVB - inching higher....good to see the upward movement.
Lockdown ending is being talked about by Boris so as soon as it starts to end there will be a big sentiment shift in to bottomed out value plays IMHO. Position early and wait ;)
People starting to pick up the huge value on offer here I think. 12p now broken so chart is free for 20p+ on technical alone.
#POLY shares are at all time highs which backs up the current Mcap alone with the BP101 upside (huge) in for free.
Big big money is being made in pharma (covid related) at the moment so that will flow to companies like this when the covid bubble pops. Lots of them wont be able to sustain their huge valuations.
RvR here second to none
Action starting, just hope it does not fizzle out.I think this is going to have a great run with a few surprises, I M O?
Could this be the week for news of some action here?
yes, I always rather turn up to the party early, get a nice position and wait for the noise surrounding the big catalyst to come.
Here it seems to me an obvious value play, with £12-14m in liquid assets that more than justifies the current MCap alone. 100% XIVI in for free, a company with a P3 approved drug that's looking for commercialisation this year (pending FDA) in a huge market ($300b in Russia alone).
On AIM you have Pharma companies at just phase 1/2 trials valued more than this and with nothing like the cash/liquid assets. P3/commercialisation stage is a huge value step change higher which is where OVB's drug is and its valued at an EV of 0..... crazy! I mean they paid $11m for it for starters
Looks like I may have jumped the gun thinking FDA would be 1-2months as the 160 working days since filing doesn't include for to/from pauses. This is looking like H2 is more likely. The EU/US trials though last guidance was mid year for that. (this is a huge $2.25b market).